Active	Status	Sponsor type	Region	Phase	Filter
1 Active 4 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fellström, Bengt
Nefigard-OLE, NCT04541043 / 2020-003308-14: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301	Completed	3	119	Europe, Canada, US, RoW	Nefecon 16mg daily	Calliditas Therapeutics AB	Primary IgA Nephropathy	02/24	02/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fellström, Bengt
Nefigard-OLE, NCT04541043 / 2020-003308-14: Efficacy and Safety in Patients With Primary IgA Nephropathy Who Have Completed Study Nef-301	Completed	3	119	Europe, Canada, US, RoW	Nefecon 16mg daily	Calliditas Therapeutics AB	Primary IgA Nephropathy	02/24	02/24